Narrative review compares long-acting growth hormone to daily recombinant human GH in pediatric GH deficiencyLong-acting growth hormone matches daily shots for growing children with hormone deficiency

Children with growth hormone deficiency need regular injections to grow at a normal pace. For years, they have had to take daily shots of recombinant human growth hormone. This daily routine can be hard to manage for families. A new narrative review looked at long-acting growth hormone formulations as an alternative. These newer medicines are designed to last longer in the body so children do not need to inject themselves every single day. The review compared these long-acting options to the standard daily recombinant human growth hormone therapy. The analysis focused on how well the drugs helped children grow and how safe they were to use. The findings suggest that long-acting growth hormone promotes linear growth just as effectively as the daily version. Families might find the less frequent dosing intervals much easier to handle. The review also checked the safety profile of the new medicines. It found that the long-acting options had a safety profile comparable to the daily therapy. There were no specific adverse events or discontinuations highlighted in the review text provided. This means the new option does not seem to carry extra risks. However, the review was a narrative review and did not report specific numbers or statistical certainty. The evidence comes from looking at existing reports rather than running a single new trial. This type of review helps doctors see the big picture of what is available for patients. It shows that a different dosing schedule is a viable choice for growing children.